BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16432311)

  • 21. Phospholipid surfaces regulate the delivery of substrate to tissue factor:VIIa and the removal of product.
    Hathcock JJ; Rusinova E; Andree H; Nemerson Y
    Blood Cells Mol Dis; 2006; 36(2):194-8. PubMed ID: 16529959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
    Lindhout T; Franssen J; Willems G
    Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography.
    Audu P; Nielsen VG; Armstead V; Powell G; Kim J; Kim L; Mehta M
    Anesth Analg; 2006 Oct; 103(4):841-5. PubMed ID: 17000790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation.
    Kjalke M; Monroe DM; Hoffman M; Oliver JA; Ezban M; Hedner U; Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S21-5. PubMed ID: 9819025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A model for the stoichiometric regulation of blood coagulation.
    Hockin MF; Jones KC; Everse SJ; Mann KG
    J Biol Chem; 2002 May; 277(21):18322-33. PubMed ID: 11893748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of the tissue factor pathway in initiation of coagulation.
    Mann KG; van't Veer C; Cawthern K; Butenas S
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S3-7. PubMed ID: 9819022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.
    Hedner U; Erhardtsen E
    Ann Med; 2000 Dec; 32 Suppl 1():68-72. PubMed ID: 11209985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
    Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An all-atom solution-equilibrated model for human extrinsic blood coagulation complex (sTF-VIIa-Xa): a protein-protein docking and molecular dynamics refinement study.
    Venkateswarlu D; Duke RE; Perera L; Darden TA; Pedersen LG
    J Thromb Haemost; 2003 Dec; 1(12):2577-88. PubMed ID: 14750502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probing the S2 site of factor VIIa to generate potent and selective inhibitors: the structure of BCX-3607 in complex with tissue factor-factor VIIa.
    Krishnan R; Kotian PL; Chand P; Bantia S; Rowland S; Babu YS
    Acta Crystallogr D Biol Crystallogr; 2007 Jun; 63(Pt 6):689-97. PubMed ID: 17505107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progesterone utilizes distinct membrane pools of tissue factor to increase coagulation and invasion and these effects are inhibited by TFPI.
    Henriquez S; Calderon C; Quezada M; Oliva B; Bravo ML; Aranda E; Kato S; Cuello MA; Gutiérrez J; Quest AF; Owen GI
    J Cell Physiol; 2011 Dec; 226(12):3278-85. PubMed ID: 21344386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phospholipid regulates the activation of factor X by tissue factor/factor VIIa (TF/VIIa) via substrate and product interactions.
    Hathcock JJ; Rusinova E; Gentry RD; Andree H; Nemerson Y
    Biochemistry; 2005 Jun; 44(22):8187-97. PubMed ID: 15924438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.
    Hackeng TM; Seré KM; Tans G; Rosing J
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3106-11. PubMed ID: 16488980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses.
    Morel O; Morel N; Freyssinet JM; Toti F
    Platelets; 2008 Feb; 19(1):9-23. PubMed ID: 18231934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
    Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
    Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Models of blood coagulation.
    Mann KG; Brummel-Ziedins K; Orfeo T; Butenas S
    Blood Cells Mol Dis; 2006; 36(2):108-17. PubMed ID: 16500122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III.
    Lu G; Broze GJ; Krishnaswamy S
    J Biol Chem; 2004 Apr; 279(17):17241-9. PubMed ID: 14963035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transmission of a procoagulant signal from tissue factor-bearing cell to platelets.
    Monroe DM; Hoffman M; Roberts HR
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):459-64. PubMed ID: 8839998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The tissue factor requirement in blood coagulation.
    Orfeo T; Butenas S; Brummel-Ziedins KE; Mann KG
    J Biol Chem; 2005 Dec; 280(52):42887-96. PubMed ID: 16215234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.